Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 644

2.

A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.

Norkus D, Miller A, Kurtinaitis J, Haverkamp U, Popov S, Prott FJ, Valuckas KP.

Strahlenther Onkol. 2009 Nov;185(11):715-21. doi: 10.1007/s00066-009-1982-z. Epub 2009 Nov 10.

PMID:
19899003
3.

Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer.

Soumarová R, Homola L, Stursa M, Perková H.

Neoplasma. 2006;53(5):410-7.

PMID:
17013535
4.

Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.

Zelefsky MJ, Nedelka MA, Arican ZL, Yamada Y, Cohen GN, Shippy AM, Park JJ, Zaider M.

Brachytherapy. 2008 Jan-Mar;7(1):1-6. doi: 10.1016/j.brachy.2007.12.002.

PMID:
18299108
5.

[Acute adverse effects of high dose brachytherapy in combination with external radiotherapy in localized prostate cancer].

Soumarová R, Homola L, Stursa M, Perková H.

Cas Lek Cesk. 2006;145(1):43-9. Czech.

PMID:
16468241
6.

Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.

Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Keller B, Danjoux C, Szumacher E, Thomas G.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):811-7. doi: 10.1016/j.ijrobp.2009.05.054. Epub 2009 Oct 14.

PMID:
19836166
7.

Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.

Valero J, Cambeiro M, Galán C, Teijeira M, Romero P, Zudaire J, Moreno M, Ciérvide R, Aristu JJ, Martínez-Monge R.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):386-92. doi: 10.1016/j.ijrobp.2009.01.059. Epub 2009 May 8.

PMID:
19427741
8.

A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.

Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H.

Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):804-9. Epub 2005 Nov 14.

PMID:
16289906
9.

Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.

Morimoto M, Yoshioka Y, Konishi K, Isohashi F, Takahashi Y, Ogata T, Koizumi M, Teshima T, Bijl HP, van der Schaaf A, Langendijk JA, Ogawa K.

Tumori. 2014 May-Jun;100(3):265-71. doi: 10.1700/1578.17198.

PMID:
25076236
10.
11.

A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.

Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):400-8.

PMID:
15667959
12.

Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy.

Chou RH, Wilder RB, Ji M, Ryu JK, Leigh BR, Earle JD, Doggett RL, Kubo HD, Roach M, deVere White RW.

Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):115-9.

PMID:
10758312
13.

Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.

Fang FM, Wang YM, Wang CJ, Huang HY, Chiang PH.

Jpn J Clin Oncol. 2008 Jul;38(7):474-9. doi: 10.1093/jjco/hyn056. Epub 2008 Jul 11.

PMID:
18621848
14.

Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.

Karlsdóttir A, Muren LP, Wentzel-Larsen T, Dahl O.

Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1478-86. Epub 2007 Dec 3.

PMID:
18060703
15.

High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.

Deger S, Boehmer D, Roigas J, Schink T, Wernecke KD, Wiegel T, Hinkelbein W, Budach V, Loening SA.

Eur Urol. 2005 Apr;47(4):441-8. Epub 2005 Jan 18.

PMID:
15774239
16.

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814-9. doi: 10.1016/j.ijrobp.2008.01.010. Epub 2008 Apr 11.

PMID:
18407435
17.

Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9. doi: 10.1016/j.ijrobp.2007.11.044.

PMID:
18313526
18.

Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.

Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e795-801. doi: 10.1016/j.ijrobp.2011.11.040. Epub 2012 Feb 11.

PMID:
22330999
19.

Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.

Kälkner KM, Wahlgren T, Ryberg M, Cohn-Cedermark G, Castellanos E, Zimmerman R, Nilsson J, Lundell M, Fowler J, Levitt S, Hellström M, Nilsson S.

Acta Oncol. 2007;46(7):909-17.

PMID:
17917823
20.

Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.

Lee WR, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H.

Cancer. 2007 Apr 15;109(8):1506-12.

Supplemental Content

Support Center